Yahoo Web Search

  1. The Opioid Crisis Can’t Be Engineered Away

    Bloomberg via Yahoo FinanceAug 06 17:02 PM

    Mallinckrodt Plc announced on Tuesday that it’s suspending a planned spinoff of its generic and opioid drug unit. The update overshadowed second-quarter earnings that beat Wall ...

  2. Mallinckrodt Enrolls First Patient in Liver Disease Study

    Zacks via Yahoo FinanceAug 13 15:53 PM

    Mallinckrodt plc MNK announced that it has enrolled the first patient in a phase IIa study on its investigational oral drug MNK-6106 (L-ornithine phenylacetate) for treating hepatic ...

  3. Company News For Aug 6, 2019

    Zacks via Yahoo FinanceAug 06 14:16 PM

    Care Company EPC lost 4.7% after the company reported third quarter fiscal 2019 revenues of $609 million, lower than the Zacks Consensus Estimate of $614 million Shares of Mallinckrodt ...

  4. (NASDAQ: ACER) Aclaris Therapeutics Inc (NASDAQ: ACRS) Actinium Pharmaceuticals Inc (NYSE: ATNM) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) Adaptive Biotechnologies Corp (NASDAQ ...

  5. Mallinckrodt: 2Q Earnings Snapshot

    Associated Press via Yahoo FinanceAug 06 10:15 AM

    The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $2.10 per share. The specialty pharmaceutical company ...

  6. Edited Transcript of MNK earnings conference call or presentation 6-Aug-19 12:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceAug 06 22:24 PM

    Q2 2019 Mallinckrodt Plc Earnings Call STAINES Aug 6, 2019 (Thomson StreetEvents) -- Edited Transcript of Mallinckrodt Plc earnings conference call or presentation ...

  7. Mallinckrodt suspends plans to spin off generics unit

    Reuters via Yahoo FinanceAug 06 10:15 AM

    Mallinckrodt Plc said on Tuesday it has suspended plans to spin off its specialty generics business, citing uncertainties tied to the opioid litigation and current market conditions ...

  8. Drugmaker Mallinckrodt Plc said on Tuesday it has suspended plans to spin off its specialty generics business, citing increasing uncertainties tied to opioid litigation. Mallinckrodt ...

  9. (IPOed July 1) Acer Therapeutics Inc (NASDAQ: ACER) Aclaris Therapeutics Inc (NASDAQ: ACRS) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) Adial Pharmaceuticals Inc (NASDAQ: ADIL) ...

  10. (NASDAQ: GHSI)(announced $5.2 million common stock offering) Haemonetics Corporation (NYSE: HAE) Hemispherx BioPharma, Inc (NYSE: HEB) Mallinckrodt PLC (NYSE: MNK) Meridian Bioscience ...